Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

BEAM

Beam Therapeutics Inc

Dec 11 • 04:00PM ET

28.90

Dollar change -1.30
Percentage change -4.30	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA EDIT ALNY SRPT SGMO BLUE CLLS VYGR ADVM

| Held by: ARKK IWM XBI ARKG VTI VB VXF IWN VBK IBB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.76	Insider Own	12.25%	Shs Outstand	82.56M	Perf Week	11.07%
Market Cap	2.39B	Forward P/E	-	EPS next Y	-4.84	Insider Trans	-2.16%	Shs Float	72.66M	Perf Month	-4.78%
Income	-143.59M	PEG	-	EPS next Q	-1.27	Inst Own	81.95%	Short Float	14.70%	Perf Quarter	18.44%
Sales	349.64M	P/S	6.84	EPS this Y	-174.65%	Inst Trans	5.98%	Short Ratio	10.13	Perf Half Y	10.90%
Book/sh	9.58	P/B	3.02	EPS next Y	-2.45%	ROA	-11.67%	Short Interest	10.68M	Perf Year	8.44%
Cash/sh	11.18	P/C	2.58	EPS next 5Y	-3.70%	ROE	-18.29%	52W Range	20.84 - 49.50	Perf YTD	6.17%
Dividend Est.	-	P/FCF	-	EPS past 5Y	5.58%	ROI	-15.27%	52W High	-41.62%	Beta	1.90
Dividend TTM	-	Quick Ratio	5.69	Sales past 5Y	43297.50%	Gross Margin	93.75%	52W Low	38.68%	ATR (14)	2.01
Dividend Ex-Date	Feb 04, 2014	Current Ratio	5.69	EPS Y/Y TTM	58.80%	Oper. Margin	-52.25%	RSI (14)	58.52	Volatility	8.71% 7.47%
Employees	436	Debt/Eq	0.20	Sales Y/Y TTM	328.73%	Profit Margin	-41.07%	Recom	1.89	Target Price	49.20
Option/Short	Yes / Yes	LT Debt/Eq	0.19	EPS Q/Q	3.53%	Payout	-	Rel Volume	1.34	Prev Close	30.20
Sales Surprise	-1.70%	EPS Surprise	1.12%	Sales Q/Q	-17.01%	Earnings	Nov 05 BMO	Avg Volume	1.05M	Price	28.90
SMA20	9.80%	SMA50	15.48%	SMA200	9.59%	Trades		Volume	1,392,489	Change	-4.30%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-06-24	Upgrade	Leerink Partners	Market Perform → Outperform	$27 → $39
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jul-23-24	Initiated	H.C. Wainwright	Buy	$80
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight	$38 → $40
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral	$35
Dec-08-23	Downgrade	Jefferies	Buy → Hold	$75 → $30
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform	$75 → $20
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Mar-21-23	Initiated	Bernstein	Mkt Perform	$37
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$62
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$61 → $66
Dec-13-22	Initiated	Citigroup	Buy	$62
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$41
Apr-28-22	Initiated	Credit Suisse	Neutral	$62
Jan-05-22	Initiated	Guggenheim	Buy	$130
Oct-19-21	Initiated	SVB Leerink	Outperform	$117
Sep-24-21	Resumed	Stifel	Buy	$85 → $120
Sep-10-21	Initiated	BofA Securities	Buy	$150
May-11-21	Initiated	Redburn	Buy
May-04-21	Initiated	RBC Capital Mkts	Sector Perform	$85

Show Previous Ratings

Dec-11-24 12:01PM	Why Beam Therapeutics (BEAM) Is the Worst ARK Stock to Buy According to Short Sellers (Insider Monkey)
Dec-09-24 11:10AM	Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains (Benzinga)
07:15AM	ASH24: Darzalex in smoldering myeloma, Mercks ADC data and Novos sickle cell drug (BioPharma Dive)
Dec-08-24 01:45PM	Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-07-24 11:30AM	Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
07:00AM	Loading…
Dec-06-24 07:00AM	Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer (GlobeNewswire) +5.49%
Dec-05-24 11:30AM	Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report? (Zacks)
Dec-04-24 07:00AM	Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader (GlobeNewswire)
Nov-12-24 04:01PM	Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference (GlobeNewswire) -7.94%
Nov-07-24 06:26AM	Beam Therapeutics upgraded to Outperform from Market Perform at Leerink (TipRanks)
Nov-06-24 02:12AM	Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: Promising BEACON Trial Results ... (GuruFocus.com) +11.24%
01:40AM	Q3 2024 Beam Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-05-24 03:37PM	Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial (Benzinga)
09:00AM	Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
07:40AM	Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Loading…
06:30AM	Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs (GlobeNewswire)
04:18AM	Sickle cell patient dies in Beam study of base editing therapy (BioPharma Dive)
Oct-31-24 03:50AM	Beam Therapeutics (BEAM): Promising Gene Editing Stock with Base Editing Technology (Insider Monkey)
Oct-29-24 06:30AM	Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting (GlobeNewswire)
Oct-23-24 08:47AM	Beam Therapeutics (BEAM): A Small-Cap Leader in Precision Genetic Medicine (Insider Monkey)
Oct-17-24 03:05PM	State Street Corp's Strategic Acquisition in Beam Therapeutics Inc (GuruFocus.com) -8.77%
Sep-05-24 11:31AM	Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report? (Zacks)
Aug-14-24 10:27AM	Beam Therapeutics Inc. (BEAM): Pioneering Genetic Medicine with CRISPR Technology (Insider Monkey)
Aug-09-24 10:19AM	3 Gene Editing Stocks with Potential to Transform Medicine (InvestorPlace)
Aug-07-24 10:50AM	Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss (Zacks)
Aug-06-24 01:54PM	BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q2 2024 (InvestorPlace)
07:45AM	Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-26-24 07:43AM	Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock? (Zacks)
Jul-24-24 06:28PM	Beam Therapeutics Stock Earns RS Rating Jump To 85 (Investor's Business Daily) +7.92%
08:53AM	Loading…
08:53AM	CRISPR Therapeutics Nears 52-Week Low. Time to Buy? (TipRanks)
08:23AM	Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40 (InvestorPlace)
Jul-22-24 04:45PM	3 Gene Editing Stocks Shaping the Future of Medicine (InvestorPlace) +12.09%
Jul-17-24 07:45AM	Caribou lays off staff; Roche walks away from Relay (BioPharma Dive)
Jul-16-24 10:12AM	Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines (Zacks) +6.52%
Jul-15-24 06:30AM	Beam Therapeutics Announces Transition of Chief Financial Officer (GlobeNewswire)
Jul-11-24 12:56PM	Here's Why You Should Invest in Beam Therapeutics (BEAM) Now (Zacks) +8.01%
Jul-09-24 12:00PM	Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
07:00AM	The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024 (InvestorPlace)
06:25AM	3 Stocks With the Potential to 10X Your Money (InvestorPlace)
Jul-04-24 02:13PM	FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals (InvestorPlace)
Jul-03-24 09:12AM	3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030 (InvestorPlace)
Jun-27-24 10:02PM	You've Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever. (InvestorPlace)
10:26AM	Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study (Zacks)
Jun-26-24 06:30AM	Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Jun-14-24 03:00AM	Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease (GlobeNewswire)
Jun-06-24 11:31AM	Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report? (Zacks)
May-30-24 06:30AM	Beam Therapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 04:00PM	Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress (GlobeNewswire)
May-13-24 02:18PM	15 Best ARK Stocks To Buy Now (Insider Monkey) +12.98%
May-09-24 06:49AM	Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine (InvestorPlace)
May-08-24 10:52AM	Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss (Zacks)
06:30AM	Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference (GlobeNewswire)
May-07-24 09:02PM	Beam Therapeutics Inc (BEAM) Reports Q1 2024 Earnings: A Detailed Overview (GuruFocus.com)
01:54PM	BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
10:17AM	Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates (MT Newswires)
06:30AM	Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results (GlobeNewswire)
May-01-24 10:01AM	Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Mar-28-24 11:30AM	Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report? (Zacks)
Mar-26-24 06:30AM	Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Feb-28-24 06:30AM	Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences (GlobeNewswire)
Feb-27-24 04:01PM	Beam Rockets 26%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug (Investor's Business Daily) +25.89%
02:57PM	Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat (Investor's Business Daily)
12:33PM	Beam Shares Rise As Q4 Results Beat Street (RTT News)
07:11AM	Beam Therapeutics Inc (BEAM) Reports Strong Year-End Financials with Key Clinical Milestones on ... (GuruFocus.com)
06:30AM	Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones (GlobeNewswire)
Feb-20-24 10:00AM	Earnings Preview: Beam Therapeutics Inc. (BEAM) Q4 Earnings Expected to Decline (Zacks)
Feb-16-24 02:46PM	Beam Therapeutics Stock Shows Healthy Relative Strength Improvement (Investor's Business Daily)
Feb-10-24 05:09PM	Top 11 CRISPR Stocks To Invest In (Insider Monkey)
Feb-07-24 07:35AM	3 Biotech Stocks to Buy on the Dip: February 2024 (InvestorPlace)
Feb-05-24 06:30AM	Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-29-24 06:21PM	Why Beam Therapeutics Stock Zoomed 17% Higher Today (Motley Fool) +16.47% -8.66%
Jan-16-24 01:51PM	Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market (InvestorPlace)
09:00AM	3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street (Motley Fool)
Jan-11-24 04:38PM	3 Stocks to Buy in the Booming Field of Gene Editing (InvestorPlace)
Jan-08-24 06:30AM	Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones (GlobeNewswire) +6.87%
05:52AM	4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024 (Motley Fool)
Jan-02-24 06:30AM	Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-27-23 10:30AM	2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street (Motley Fool)
Dec-15-23 10:22AM	11 Most Promising Biotech Stocks to Buy According to Analysts (Insider Monkey)
Dec-14-23 06:30AM	Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors (GlobeNewswire) +5.34%
Dec-08-23 11:30AM	Why Is Beam Therapeutics Inc. (BEAM) Up 29.5% Since Last Earnings Report? (Zacks) -8.17%
Nov-30-23 09:55AM	Wall Street Analysts Believe Beam Therapeutics Inc. (BEAM) Could Rally 81.29%: Here's is How to Trade (Zacks)
Nov-23-23 11:03AM	Beam Therapeutics Inc's Chief Legal Officer Christine Bellon Sells 10,000 Shares (GuruFocus.com)
09:42AM	14 Best Short-Term Stocks to Invest In (Insider Monkey)
Nov-20-23 05:43PM	The 3 Best Gene Editing Stocks on the Frontier of Medicine (InvestorPlace) +11.98% -9.14%
Nov-18-23 07:15AM	Is Beam Therapeutics Stock a Buy Now? (Motley Fool)
06:49AM	3 Monster Stocks in the Making (Motley Fool)
Nov-17-23 12:00PM	What Makes Beam Therapeutics Inc. (BEAM) a New Buy Stock (Zacks) +10.81%
Nov-14-23 05:50AM	Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks (Motley Fool) +11.90%
Nov-10-23 09:55AM	Does Beam Therapeutics Inc. (BEAM) Have the Potential to Rally 139.76% as Wall Street Analysts Expect? (Zacks)
Nov-09-23 01:04PM	Beam Therapeutics (BEAM) Q3 Earnings & Revenues Beat Estimates (Zacks)
Nov-08-23 06:30AM	Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference (GlobeNewswire) -8.36%
06:30AM	Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-06-23 08:02AM	Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners (Investor's Business Daily)
Nov-05-23 08:30AM	2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now (Motley Fool)
Nov-01-23 05:40AM	Inside Cathie Woods Portfolio: 3 Stocks She Is Betting Millions On (InvestorPlace)
Oct-31-23 07:09PM	Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today (Motley Fool) +10.62%
04:04PM	Verve Stock Soars On $250 Million Eli Lilly Deal (Investor's Business Daily)
10:01AM	Will CRISPR Therapeutics AG (CRSP) Report Negative Q3 Earnings? What You Should Know (Zacks)

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ciaramella Giuseppe	President	Nov 06 '24	Sale	26.36	51,110	1,347,050	109,150	Nov 08 04:10 PM
Ciaramella Giuseppe	President	Oct 14 '24	Option Exercise	2.00	41,754	83,594	211,370	Oct 16 04:44 PM
Ciaramella Giuseppe	President	Oct 14 '24	Sale	26.27	51,110	1,342,752	160,260	Oct 16 04:44 PM
Giuseppe Ciaramella	Officer	Oct 14 '24	Proposed Sale	24.65	102,220	2,519,723		Oct 15 11:37 AM
Burrell Terry-Ann	Officer	Oct 07 '24	Proposed Sale	23.00	185,565	4,267,995		Oct 07 05:00 PM
Bellon Christine	Chief Legal Officer	Oct 01 '24	Sale	23.48	385	9,040	104,209	Oct 02 05:52 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Oct 01 '24	Sale	23.48	289	6,785	44,931	Oct 02 05:51 PM
Evans John M.	CEO	Sep 30 '24	Sale	24.60	60,000	1,476,024	938,659	Oct 02 05:49 PM
JOHN M EVANS	Officer	Sep 30 '24	Proposed Sale	24.60	60,000	1,476,024		Sep 30 04:51 PM
Simon Amy	Chief Medical Officer	Jul 02 '24	Sale	22.95	748	17,167	68,805	Jul 03 04:05 PM
Simon Amy	Chief Medical Officer	Jul 01 '24	Sale	23.76	502	11,928	69,553	Jul 03 04:05 PM
Evans John M.	CEO	Jun 27 '24	Sale	24.50	60,000	1,470,156	998,343	Jun 28 04:15 PM
Simon Amy	Chief Medical Officer	Apr 02 '24	Sale	30.54	16,530	504,851	70,060	Apr 03 07:43 PM
Simon Amy	Chief Medical Officer	Apr 01 '24	Sale	32.13	7,157	229,954	86,590	Apr 03 07:43 PM
Bellon Christine	Chief Legal Officer	Apr 01 '24	Sale	32.12	3,401	109,240	104,594	Apr 03 07:40 PM
Burrell Terry-Ann	Chief Financial Officer	Apr 01 '24	Sale	32.12	5,446	174,926	70,137	Apr 03 07:39 PM
Evans John M.	CEO	Apr 01 '24	Sale	32.13	18,102	581,617	1,058,343	Apr 03 07:36 PM
Ciaramella Giuseppe	President	Apr 01 '24	Sale	32.12	4,534	145,632	169,616	Apr 03 07:33 PM
Evans John M.	CEO	Mar 28 '24	Sale	33.86	60,000	2,031,402	998,262	Apr 01 04:10 PM
FMR LLC	See Remark 1	Feb 14 '24	Sale	30.55	900,000	27,496,912	1,235,511	Feb 15 02:34 PM
FMR LLC	See Remark 1	Feb 13 '24	Sale	30.76	1,565	48,139	2,771,913	Feb 15 02:34 PM
Evans John M.	CEO	Jan 31 '24	Sale	25.33	60,000	1,519,800	1,058,262	Feb 02 04:05 PM
Bellon Christine	Chief Legal Officer	Jan 03 '24	Sale	26.42	1,907	50,383	80,495	Jan 05 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BEAM

Beam Therapeutics Inc

Upgrade your FINVIZ experience